MonoSol Rx Leadership Presented PharmFilm Buccal Delivery Clinical Update at Leading Pharmaceutical Technology Meeting

Chief Innovation & Technology Officer A. Mark Schobel was a lead presenter at the International Association for Pharmaceutical Technology seminar in Innsbruck, Austria

Warren, NJ (Feb. 9, 2014) – MonoSol Rx, the developer of PharmFilm® drug delivery technology, presented the Company's technology recently at the International Association for Pharmaceutical Technology (IAPT) in Innsbruck, Austria. MonoSol Rx Chief Innovation & Technology Officer A. Mark Schobel was a lead presenter at the ODx and MBx - Orodispersible and Mucoadhesive Buccal Formulations seminar hosted by the IAPT. His session, titled, "Mucoadhesive Buccal Films" (MBFs), highlighted MonoSol's PharmFilm delivery technology, product development strategy and pipeline including the MSRX-301 transbuccal oral insulin film currently moving toward Phase II clinical trials.

"The IAPT is a leading organization committed to the development of innovative pharmaceutical technologies. I was honored to present our game-changing technology to an audience of thought leaders in pharmaceutical product and business development, manufacturing and regulatory affairs at this prestigious seminar," Schobel said. "This conference is one of the largest dedicated exclusively to orodispersible and mucoadhesive buccal formulations in drug development and drew a significant crowd from throughout the global pharma industry. The large participation reflected the growing market interest in oral film-based drug product technologies as an optimal delivery approach for a number of compounds to treat an expanding range of indications."

The IAPT is a nonprofit scientific society committed to furthering scientific research for the development, manufacture, distribution and use of medical products. The organization's ODx and MBx seminar will focus on recent innovations in formulation development, manufacturing and quality control, biopharmaceutical methods for characterization and regulatory issues.

MonoSol Rx currently has two commercialized oral film products: Suboxone® (Buprenorphine/Naloxone) for the treatment of opioid dependence and Zuplenz® (Ondansetron) for treatment of nausea and vomiting in patients receiving chemotherapy. In addition, the Company's pipeline includes a transbuccal oral insulin film product for blood glucose management in diabetics and an oral film for testosterone replacement to treat hypogonadism, both of which are currently in Phase II trials. The Company has four additional complex molecule product candidates currently in various stages of preclinical development.

More information about the ODx and MBx - Orodispersible and Mucoadhesive Buccal Formulations seminar can be found at http://www.apv-mainz.de/. For more information about MonoSol Rx, visit http://www.monosolrx.com.

About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to develop products which address the unmet needs of patients.  PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs.  The Company's leadership in film drug delivery is supported by strong intellectual property, a pipeline of prescription formulations based on PharmFilm® technology, and two FDA approvals — Zuplenz®, the first approved prescription oral soluble film for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting, and Suboxone® sublingual film, the first sublingual film product for the treatment of opioid dependence.  For press releases and other company information visit www.monosolrx.com.

About The Association for Pharmaceutical Technology

The Association for Pharmaceutical Technology (APV) is a nonprofit scientific society. Its main objective is to deepen the scientific evidence on the development, manufacture, distribution and use of medicinal products and to communicate this knowledge.

Please complete this form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing info@aquestive.com or by calling 1-908-561-1900.

Please complete the form below and click SEND to receive a copy of “Overcoming Solubility and Permeability Challenges,” a case study detailing the achievements made by Aquestive’s formulation team to create the diazepam buccal film.

  • To subscribe to receive marketing updates about diazepam buccal film and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form to receive a demonstration kit for our PharmFilm® technology.

  • To subscribe to receive marketing updates about our PharmFilm® technology and other products and services from Aquestive, please complete the form below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete this form:

  • To subscribe to receive marketing updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. If for any reason you no longer wish to receive information on Aquestive-sponsored clinical trials, you can contact us at any time by emailing clinicaltrials@aquestive.com.

Whether we are partnering to out license our PharmFilm® technology or in-licensing adjacent assets, Aquestive works hand-in-hand with our partners to address their toughest clinical and business challenges. To learn more, please complete the following form:

  • To subscribe to receive information updates about products and services from Aquestive Therapeutics, or to receive information about Aquestive-sponsored clinical trials, please check the box below. Please also review our privacy policy, which describes how we use and process your data. You may also contact us at any time by emailing busdev@aquestive.com.

Please complete the form below and click submit to receive a copy of “The Art of LGS Book.”